Correspondence on ''the unrecognized epilepsy spectrum: the effects of levetiracetam on neuropsychological functioning in relation to subclinical spike production''.
Duane
Drake D
DD
D000927:Anticonvulsants / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects / Q000254:growth & development / Q000503:physiopathology; D002648:Child; D003071:Cognition / Q000187:drug effects / Q000502:physiology; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology* / Q000503:physiopathology; D002658:Developmental Disabilities / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D004569:Electroencephalography / Q000187:drug effects; D004827:Epilepsy / Q000150:complications* / Q000188:drug therapy* / Q000503:physiopathology; D005071:Evoked Potentials / Q000187:drug effects / Q000502:physiology; D006801:Humans; D000077287:Levetiracetam; D009483:Neuropsychological Tests; D018697:Nootropic Agents / Q000494:pharmacology / Q000627:therapeutic use; D010889:Piracetam / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D020127:Recovery of Function / Q000187:drug effects / Q000502:physiology
D000927:Anticonvulsants; D018697:Nootropic Agents; D000077287:Levetiracetam; D010889:Piracetam